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ABSTRACT
Mary Grace Stewart: The Effect of Histone Deacetylase Inhibitors on Metastatic Breast Cancer Cells in Conjunction
with Clinically Relevant Chemotherapeutic Agents (Under the direction of Dr. Yu-Dong Zhou and Dr. Dale George Nagle)

Histone Deacetylases (HDACs) are enzymes charged with the job of loosening DNA
packaged around histone proteins. This gives them the opportunity to affect the
transcriptional regulation of certain cancer associated genes and proteins, but HDACs are not
limited to only DNA modification. They also target non-chromatin proteins in the cytoplasm,
and have been closely linked to the many pathways involved in metastatic breast cancer such
as apoptosis evasion, cell migration, and angiogenesis. HDAC’s effect on important
cytoplasmic proteins could play a huge role in the largely unknown mechanisms of metastatic
breast cancer. HDAC inhibitors are a rising class of chemotherapeutic agents. In this
research, HDAC inhibitors selective for cytoplasmic target proteins are used in conjunction
with nuclear based HDAC inhibitors and known microtubule stabilizers and destabilizers to
test and explore the effects of HDAC inhibition on MDA-MB-231-derived metastatic breast
cancer cell lines BoM-1833 (BoM) and LM-4175 (LM), and in MCF-7-derived metastatic
breast cancer cell line MCF-7 BoM. Through viability, clonogenic, and combination assays,
the HDAC inhibitors were not found to have complete inhibition of the tumor cells at any of
the tested concentrations but show a trend suggesting potential effects on tumor inhibition at
higher concentrations. There is also some evidence supporting a potential significance of
HDAC inhibitors on ER+ breast cancer cells. Clonogenic assays upheld the inhibitory results
of HDAC inhibitors on metastatic breast cancer cells, and emphasized the increased
effectiveness of higher concentrations of HDAC inhibitors. Combination assays showed a
trend towards antagonistic effects between HDAC inhibitors and microtubule stabilizes.
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INTRODUCTION:
BREAST CANCER:
In 2019, the American Cancer Society predicts that there will be 1,762,450 new
cases of breast cancer in the United States. Of these, 42,260 cases are predicted to end in
death [1]. In 2018, The World Health Organization’s International agency for Cancer
Research documented an estimated 2,088,849 cases with 626,679 deaths worldwide. Breast
cancer has the most incidences worldwide behind lung and skin cancers [2]. From 1989 to
2016, death associated with breast cancer in the U.S. was reduced by 40%. This is likely
attributed to increased awareness, earlier diagnosis, and better available treatments, but
since 2016, the death rates for women under 50 have plateaued [1]. Something new needs
to happen. Early intervention can only go so far to help women, and with a 0.4% incident
increase in the U.S. per year over recent years [1], one would expect the death rates to
begin climbing again in the future if something new doesn’t intervene.
Breast cancer, along with most all cancers, is caused by abnormal, out of control
cell growth. In breast cancer, the growth and invasion of the cancerous cells can be denoted
by staging. Small localized cancerous tumors in the breast duct or the mammary glands
that have not spread or have spread minimally to the most commonly cancer associated
lymph node, the sentinel lymph node, are classified as stage 1 breast cancer. Stage 2 tumors
are larger and have generally spread to a few more nearby lymph nodes. Stage 3 tumors
are even larger and have spread to most all nearby lymph nodes or have begun growing
into the nearby skin and muscle tissues surrounding the breast. Stage 4 is metastatic breast
cancer, which spreads to other parts of the body [4] (figure 1.1).
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Figure 1 Stages of Breast Cancer (Siddique, M. (2017, April))
Breast tumors present as a mass or lump in the breast. The mass is usually hard and
irregular and isn’t associated with pain, but some can be soft, round, and painful. This is
why diagnostic tools are so important. Most healthcare specialists use mammograms,
specialized x-rays that can help visualize breast tissue and structures, and biopsies to
identify the malignancy of tumors. These and more technological advances have helped to
detect disease early on and reduce the incidence of metastasis. If caught early enough, these
cancers can be very treatable. Some examples of treatments are chemotherapy, hormone
therapy, targeted drug therapy, and oncoplastic surgery, in which the surgeon has to remove
a tumor but reconstructs the breast afterward. The removal of a tumor from the breast is
called a lumpectomy, which, along with partial mastectomies, can be done with early stage
tumors. Later stage, larger tumors require full mastectomies and full reconstruction [4].
Clinically, breast cancer tumors can be classified by their genetic variation and
receptor types. They can be broken down into four subgroups: luminal A, luminal B, Her2+
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(human epidermal growth factor receptor 2-positive), and basal-like. Luminal A breast
tumors have estrogen and progesterone receptors and can be treated with hormone therapy
and chemotherapy. Luminal B tumors have estrogen receptors and are Her2 positive. These
are generally treated with chemotherapy, hormone therapy, and targeted Her2 therapy.
Her2+ tumors do not have hormone receptors but are positive for the Her2 oncogene which
codes for a growth promoting Her2 protein. These tumors are approached with targeted
therapy to shut down the Her2 protein in addition to chemotherapy [5]. Basal-like tumors
are “triple-negative.” They don’t have estrogen receptors or progesterone receptors, and
they do not overexpress Her2. Often, mutations in the BRCA1 gene, a tumor suppressor
gene, are associated with triple-negative breast cancer. These are difficult to treat because
there are no available target proteins or receptors for therapy. Chemotherapy is the
treatment choice for basal like tumors. These are usually larger and more severe at
presentation and are typically diagnosed with poorer overall outcomes [6]. Another, less
common type of breast cancer is inflammatory breast cancer (IBC) which is associated
with advanced stage presentation and axillary lymph node involvement which leads to a
greater chance of metastasis. About 35% of IBC cases have distant metastasis which may
be contributed to increased levels of Her2 protein and pro-angiogenic factors. There are so
many types of breast cancer because the tumors have such heterogeneous pathology and
genetic profiles [7].
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METASTASIS:
When breast cancer cells break off the primary tumor, they can enter into the
lymphatic or blood vasculature and disseminate to other organs. This is known as
metastasis or stage 4 breast cancer. Breast cancer cells generally metastasize to the bones,
lungs, liver, and brain. Some cases of metastasis present at initial diagnosis, which is
known as de novo metastasis and generally results from a late diagnosis, but most occur
after an initial diagnosis and treatment course. Some breast cancer cells can evade
treatment and travel to other organs [8]. It is important to note that cancer that has
metastasized to the bone, for example, is not bone cancer. It is still breast cancer and has
the same genetic makeup as the primary breast tumor.
In order to travel over the body, epithelial breast cancer cells have to undergo a
differentiation into mesenchymal stem cells. This differentiation is known as epithelial–
mesenchymal transition (EMT.) The EMT process is reversible and it plays an important
intrinsic role in organ development, wound healing, and fibrosis. The reversible nature of
EMT makes it a source of interest when looking at possible drug targets. The shift from
epithelial cells to mesenchymal stem cells results in a decrease in cell adhesions, and
increase in cytoskeleton arrangement, matrix remodeling, and motility. Mesenchymal cell
motility comes from specialized spindle morphology and cytoskeleton features [9]. There
are two schools of thought on the factors that promote dissemination. Some believe in early
dissemination and the importance of the microenvironment for selecting signaling
pathways which lead to metastasis. Others believe in late dissemination in which the
gradual mutation of the primary tumor results in the ability to metastasize [10]. Critical
steps in the initial stages of EMT are the downregulation or silencing of E-cadherins, cell-

12

cell adhesion proteins, and the upregulation of N-cadherins and matrix metalloproteinases
(MMPs), proteases that cleave endothelium proteins [11]. These steps work to break the
cancer cells away from the surrounding epithelial cells and help them degrade and weaken
the surrounding extracellular matrix (ECM). Once converted into mesenchymal stem cells,
the MMP enzymes break down the extracellular matrix and deregulate ECM remodeling
which allows the tumor to more easily invade local tissues [9]. The MMPs also help to
break down the endothelial cells of lymphatic and blood vasculature. Due to tumor
mediated angiogenesis, the blood vessels near the tumor are usually more permeable and
leaky. Once inside the vasculature, the breast cancer cells are vulnerable to immune attack.
They evade this by surrounding themselves with platelets and clotting factors. This most
likely serves a dual purpose by also protecting the cells from anoikis, a form of apoptosis
induced by the loss of cell-to-cell adhesions. Once safely in platelet clumps, the cancer
cells travel within the vasculature until they come to a target organ with an ideal
microvasculature, where the cancer cells attach to the wall of the blood or lymph vessels.
Extravasation usually happens when a platelet clump associated with tumor cells is
attracted to a weakened part of target organs microvasculature. The MMPs help to go
through the endothelium of the vessels and into the parenchyma of the target organ [10].
The mesenchymal cells may then differentiate back into epithelial cancer cells in order to
proliferate and form a tumor (figure 1.2). The target organ microenvironment must be
conducive for proliferation, for example, the growth factor VEGF (vascular endothelial
growth factor) is required to help ensure angiogenesis to support the newly growing
secondary tumor [10]. This idea is known as the “seed and soil” theory. The
microenvironment of the “soil” has to be specifically suited to the “seed” for it to grow
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[11]. One major example of an extrinsic factor of microenvironment associated with breast
cancer metastasis is hypoxia and hypoxia-inducible factors (HIFs.) These factors,
specifically HIF-1 help promote motility, intravasation, platelet clumping in the
vasculature, and formation of proper “soil” for metastatic invasion [11].

Figure 2 The significance of EMT and MET in breast cancer tumor metastasis

Ruben, B. (2015, June 22)
Secondary symptoms can precede a diagnosis of metastatic breast cancer.
Headaches, seizures, and drowsiness are associated with brain metastasis. Pain and
frequent fracturing can be a symptom of bone metastasis. In the liver, metastasis presents
with jaundice and a swelling of the abdomen. Lung metastasis is associated with chronic
shortness of breath. Treatment plans to address metastasis are often primarily aimed at
helping prolong and improve the quality of remaining life [12]. That means that all such
treatments can do to address metastasis is treat symptoms and prevent further spreading of
the cancer. Metastasis is sometimes approached surgically, but generally, based on the type
of primary cancer, it is treated with hormone therapy or chemotherapy. There are some
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newer targets that have been explored to help treat metastasis. Bevacizumab is a
monoclonal antibody to VEGF. It is an antiangiogenic therapy used to prevent the
formation of new blood vessels around tumors. It has shown an increase in progressionfree survival time. Unfortunately, bevacizumab is a high-risk option specifically for breast
cancer patients. It is associated with hemorrhaging, severely elevated blood pressure, and
heart failure in breast cancer patients [10]. Another new drug therapy is called trastuzumab
(Herceptin). It is a monoclonal antibody of the Her2+ antigen. This therapy has proven
effective in metastasis of Her2+ cancers [10]. There remains considerable room for
research and development in treating metastatic breast cancer.

HISTONE DEACETYLASES:
Eukaryotic DNA is packaged tightly together in the nucleus of every cell. Strands
of DNA wrap around positively charged proteins rich in lysine and arginine called histones.
The positive charge of histones helps to stabilize the negatively charged DNA. A histone
octamer wrapped with 146 DNA base pairs, that make up a nucleosome. The octamer
contains pairs of four core histones: H3, H4, H2A, and H2B. An H1 histone helps to ensure
the DNA is wrapped effectively around the nucleosome [13]. A nucleosome is a subunit of
chromatin, which coils tightly to form a eukaryotic chromosome.
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Figure 3 Histone structure and organization (Silk, E. (2017, May 25))
Transcriptional regulation is strongly influenced by the packaging of the DNA.
Histone modifications can affect the accessibility of DNA and therefore the expression of
genes. Acetylation is one of the ways that histones are modified. Histone acetyltransferase
protein can acetylate the tail of histones in a nucleosome. The acetylation occurs at the εamino group of conserved lysine residues at the N-terminal of histone tails. In vivo, all core
histones are acetylated, but H3, and H4 tails are more commonly acetylated than those of
H2A/H2B dimers [14]. The added acetyl group acts to mask the positivity of the histones,
loosening the tightly wrapped negatively charged DNA and exposing it for transcription.
Therefore, generally, hyperacetylation results in an increase of gene expression, whereas,
hypoacetylation results in the opposite effect [14].
Acetylation of histone tails is reversible and balanced by the activities of histone
acetyltransferases (HATs), and histone deacetylases (HDACs), which deacetylate the
histone tails [15]. In humans, there are 18 HDACs which are divided into four classes [13].
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Class I is made up of HDAC 1, HDAC 2, HDAC 3, and HDAC 8. These are Rpd3-like
proteins, meaning they have a similar mechanistic profile as that of the protein in Rpd3
yeast [15]. Class I HDACs are generally located in the nucleus and are ubiquitously
distributed throughout the body [16]. Class II consists of HDAC 4, HDAC 5, HDAC 6,
HDAC 7, HDAC 9, and HDAC 10. HDAC 10 and HDAC 6 are slightly different than the
rest in this class and so are subdivided as Class IIb. All of these are Hda-1-like proteins,
meaning they are similar to the Hda-1 yeast protein [15]. They can be moved between the
nucleus into the cytoplasm, which suggests a potential for involvement with non-histone
proteins. These HDACs are also expressed in a more tissue-specific fashion than Class I
[16]. Class IV, as of now, is made up of only HDAC 11 and is homologous to Class I and
II [15]. These three classes (I, II, IV) are known as the classical families (Table 1) [14].
Class III HDACs are Sir2-like proteins and have a mechanism involving NAD+, where the
classical families have a zinc-dependent mechanism for deacetylation [15].

Table 1 Classical Families of histone

Class I

HDAC 1-3
HDAC 8

Class II

HDAC 4-7
HDAC 9,10

Class IV

HDAC 11

Not only can HDACs regulate gene expression through direct deacetylation of
histones, they can also act in corepressor complexes with nuclear receptors, in direct
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interaction with transcription factors, and in the deacetylation of non-histone proteins,
making it possible for them to alter regulation of important cell functions and cellular
homeostasis [16]. Specific HDACs have been linked to metabolic, inflammatory,
immunological, cardiac, pulmonary, and neurodegenerative diseases, as well as cancer
[15]. The loss of acetyl groups on Lys16 and the trimethylation of Lys20 of Histone 4 has
been found to be a common event in human cancers. Methylation acts in opposition to
acetylation. The reduction of acetylation of certain histones has also been more specifically
linked to tumor invasion and metastasis [16]. Further exemplifying the relationship
between HDACs and cancer, some gastric, prostate, colon, and breast cancer tumor
samples have been found to have increased levels of HDAC 1. Similarly, HDAC 3 and
HDAC 6 have been linked closely to colon and breast cancer. The increased levels of
HDACs in tumor cells points to a potential involvement in the transcriptional repression of
tumor suppressor genes [16]. They are also associated with cancer cell progression and
metastasis through the modification of non-histone proteins. One example is the
transcription factor SNAIL which recruits HDAC 1 and HDAC 2 along with their
corepressor complex to repress the expression of E-cadherin, a crucial player in EMT [16].
Another non-histone target of HDACs closely linked to cancer is p53, an important tumor
suppressor protein involved in the cell cycle. The deacetylation of p53 promotes its
ubiquitination (degradation.) Without p53, cells can reenter the cell cycle with limited
restriction. This contributes to cancer cell proliferation and tumor growth [15]. Tumor
angiogenesis has also been associated with an increase in HDAC and their deacetylation
and promotion of HIF-1〈, VEGF, and MMPs which are all important proteins associated
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with tumor invasion [15]. All of this points to HDACs as prime drug targets for metastatic
cancers.
HDAC 6 is unique in its tendencies to stay in the cytoplasm and primarily
deacetylate non-histone proteins instead of chromatin proteins involved with gene
expression [17]. Among many proteins that HDAC 6 is known for targeting are alphatubulin, cortactin, Hsp90 (heat shock protein 90), ®-caderin, and survivin. These proteins
are associated with cell migration, F-actin binding, protein degradation, cell proliferation,
and suppression of apoptosis respectively [17]. Hypoacetylation of alpha-tubulin promotes
chemotactic cell movement. HDAC 6 appears to play a big role in tumor metastasis. One
indication of this idea is the relationship between HDAC 6 and human enhancer
filamentation 1(HEF1), a prometastatic scaffolding protein which phosphorylates HDAC
6, enhancing tubulin deacetylase activity and regulating cilia assembly by HDAC 6 [17].
Another role HDAC 6 plays in cells is colocalizing with G-Protein-Coupled Receptor
Kinase 2 (GRK2) and interacting in the lamellipodia of migrating cells. The increased
deacetylation of local tubulin proteins increases motility. HDAC 6 is required to modulate
the invadopodia activity and invasion in many types of cancer. There is a significant link
between higher levels of HDAC 6 in breast cancer cells and metastasis, which corresponds
to the role it seems to play in the migration and movement of the cell. It also promotes
angiogenesis by deacetylating cortactin in endothelial cells, helping to regulate migration
and sprouting of cancer cells. Additionally, it has been found to upregulate HIF-1 and
VEGF, both highly involved proteins in tumor angiogenesis [17]. HDAC 6 is also linked
with cell proliferation. HDAC 6 associates with the transcription factor Runt Related
Transcription Factor 2 (RunX2) which results in the repression of p21, a vital protein in
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the cell cycle. The cylindromatosis (CYLD) gene, is a deubiquitinating enzyme and tumor
suppressor gene. It controls cells growth, division, and cytokinesis through a-tubulin and
microtubules. It also inhibits HDAC 6. Many types of cancers are found to have decreased
levels of CYLD [17]. The regulation and repression of HDAC 6 may be a target to help
increase expression of CYLD. In addition to proliferation and migration of the cell, HDAC
6 is involved in apoptosis. They regulate the Ku70 protein through deacetylation,
preventing apoptosis. They also regulate the oncogenic protein survivin, which is expressed
primarily in ER+ breast cancer. Survivin is acetylated in the nucleus, which masks its antiapoptotic properties. HDAC 6 localizes to perinuclear regions and deacetylate the
oncogenic protein, blocking apoptosis in cancer cells [17]. All of these facets, make HDAC
6 a prime target for anticancer drugs, especially in metastatic cancer cells, but a lot is still
unknown about the mechanisms of its involvement in cancer.
The multifaceted roles of HDACs in cancer, give a wide range of anticancer drug
targets. The mechanisms of anticancer effects are not uniform, but vary with the type of
cancer being treated and with the individual inhibitor target HDAC class. There are five
classes of HDAC inhibitors: hydroxamic acids, short- chain fatty acids, benzamides, cyclic
tetrapeptides, and sirtuin inhibitors [18]. As of 2017, there were four approved HDAC
inhibitor drugs to treat cancer. The first was a hydroxamic acid called Vorinostat, or SAHA.
Vorinostat is a pan-HDAC inhibitor approved to treat cutaneous T-cell lymphoma.
Belinostat is also a hydroxamic acid-based pan-inhibitor, and it is approved to treat
peripheral T-cell lymphoma. Panobinostat is similar, but it is used in the treatment of
multiple myelomas. Romidepsin is a cyclic tetrapeptide HDAC isoform-selective inhibitor
which selects for class I HDACs. It is approved to treat cutaneous T-cell lymphoma [18].
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There are many other HDAC inhibitors still undergoing various stages of trials and testing.
One of these is Ricolinostat, a benzamide-based inhibitor, which selectively targets HDAC
6. HDAC inhibitors have been found to induce apoptosis, alter cell migration, activate cell
differentiation, impair tumor angiogenesis, and upregulate the expression of tumor
suppressor genes and proteins [18].
In this experiment we sought to look more closely at some HDAC inhibitors and
their effects over multiple breast cancer cell lines. Specifically, we wanted to explore the
behavior of HDAC inhibitors known for targeting non-histone microtubule proteins in
comparison with nuclear HDAC inhibitors and known chemotherapeutic microtubule
stabilizer and destabilizers. We tested multiple metastases lines in order to investigate the
possibility of cell-line dependency on HDAC inhibition.

METHODS
BACKGROUND RESEARCH:
The undertaking of this thesis began over two years ago in the fall semester of 2016.
We were involved in an introductory cancer research class in which we learned more about
cancer and its mechanisms. In the spring of that year, we began to subdivide our class into
specific interest groups. We began planning our approach to study the effects of HDAC
inhibition in metastatic cancer cells with literary searches of existing research and scholarly
sources. We began looking at different HDAC inhibitors and oncological compounds of
interest. The layout of our experiment started by focusing on existing drug treatments and
on the National Cancer Institute Developmental Therapeutics Program NCI-60 cell line
database, a resource which makes relevant concentration responses known for different
21

compounds on specific cell lines. Under the guidance of Dr. Zhou, we were able to look at
the available compounds and create an experimental layout. We wanted to make sure that
each class of classical families of HDACs were represented through an inhibiting
compound. We used two pan-HDAC inhibitors, an inhibitor selective to class 1 HDACs,
and an inhibitor selective for the class II HDAC 6 enzyme specifically. The HDAC 6
inhibitors were of particular interest because of HDAC 6’s known selectivity towards nonhistone microtubule targets. We also included in our experiment known microtubule
stabilizers and destabilizers in order to study them in conjunction with the activity of
HDAC specific inhibition. The comparison might give a better understanding into the
involvement of non-histone targets of HDACs such as the a-tubulin protein in
microtubules.

DRUG COMPOUNDS:

Vorinostat (SAHA)
We purchased Vorinostat from Cayman Chemical
Company. It was dissolved with DMSO to make a 10 mM stock
solution. It is a pan-HDAC inhibitor
Figure 4 Vorinostat
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Panobinostat
We purchased Panobinostat from Cayman Chemical
Company. It was dissolved with DMSO to make 100 µM stock

solution. It is a pan-HDAC inhibitor.
Figure 5 Panobinostat

Romidepsin
We purchased Romidepsin from Cayman Chemical
Company. It was dissolved with DMSO to make a 100 µM
stock solution. It is a selective inhibitor for class I HDACs.
Figure 6 Romidepsin

Ricolinostat
We purchased Ricolinostat from Selleck Chemical
Company. It was dissolved with DMSO to make a 10 mM
stock solution. It is an inhibitor selective for HDAC 6.
Figure 7 Ricolinostat
Paclitaxel (Taxol)
We purchased Paclitaxel from Sigma Aldrich. It was
dissolved with DMSO to make a 10 mM stock solution. It is a
microtubule stabilizer.
Figure 8 Paclitaxel
23

Epothilone B
We purchased Epothilone B from Selleck Chemical
Company. It was dissolved with DMSO to make a 10 mM
stock solution. It is a microtubule stabilizer.

Figure 9 Epothilone B

Colchicine
We purchased Colchicine from Sigma Aldrich. It was
dissolved with DMSO to make a 100 µM stock solution. It is a
microtubule destabilizer.

Figure 10 Colchicine

Vinblastine
We purchased Vinblastine from Sigma Aldrich. It was
dissolved with DMSO to make a 100 µM stock solution. It is a
microtubule destabilizer.

Figure 11 Vinblastine
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CELL LINES:
We looked at the effects of HDAC inhibition over three cells lines: BOM, LM, and
MCF-7-BOM. Both BOM and LM are derived from the triple-negative breast cancer cell
line, MDA-MB-231. It was originally isolated over 40 years ago from a pleural effusion in
a breast cancer patient with a metastatic relapse several years after her primary tumor
removal [19]. MDA-MB-231 is highly selective for metastasis and has specific tissue
dissemination selectivity to the bone and lung [20]. We are using a subpopulation derived
from MDA-MB-231, BOM-1833, which is highly selective for metastasis to the bone when
injected into the arterial circulation of immunodeficient mice [19]. Another derivative of
MDA-MB-231 that we used is LM-4175, a derivative cell line, which is highly aggressive
towards lung metastasis in mice [20]. MCF7-BOM is metastatic variant of derived from
MCF7, a well characterized human breast cancer cell line. MCF7 is an ER positive breast
cancer cell line that originated from a 69-year-old Caucasian female in the 1970’s [24].
Both the MDA-MB-231 variant lines (BoM-1833, LM-4175) and the MCF-7 variant line
(MCF7-BoM) were cultured in Dulbecco’s modified Eagle’s media (DMEM)/F12 that
were supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics [19]. All of the
metastases lines used in our research were first generated by Dr. J Massagué at the Sloan
Kettering Cancer Center, New York City, New York [19]. Our research group obtained
all of the metastatic clones from Dr. Kounosuke Watabe at Wake Forest University [24].
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PREPARING STOCK AND WORKING DILUTIONS:
To begin preparing the compounds for testing, we removed powdered compounds
from 4ºC and let them warm up to room temperature for weighing on an analytic balance.
Using DMSO, dimethyl sulfoxide, we prepared 10mM stock solutions for compounds with
the higher range of concentration (vorinostat, paclitaxel, epothilone B, and ricolinostat) and
00 µM stock solutions for those needing a lower range (romidepsin, panobinostat,
colchicine, and vinblastine.) Then using a serum free media, we diluted the stock solution
to the highest tested concentration at 2x final concentration in the mother plate. We
prepared the mother plate at 3.5x times of the required volume, since for the first round of
viability we were working with three 96-well plates. We used a 1:10 serial dilution to
prepare the working solutions at the lower concentrations. From the well on the mother
plate with the highest concentration, we took same volume of solution and added it to a
lower well in a stepwise fashion, and then we diluted it to the desired concentration using
serum free media, achieving the desired 350 µL end volume for each well. For example,
we took 35 µL of the 0.1 µM solution well and put in into a well with 315 µL of serum free
media to create 350 µL of 0.1 µM solution as seen in figure 12.

26

Figure 12 Serial Dilution in 96-well plate

SRB VIABILITY ASSAY:
Once we had our compounds and concentration ranges selected we ran several SRB
viability assays. The SRB, or Sulforhodamine B Assay, is a rapid, sensitive, and relatively
economical tool for looking at cell proliferation and chemosensitivity. To start the assay,
the cells were taken out of incubator, the conditioned media removed, and the cells
detached withtrypsin (1 ml per 10 cm plate), then the reaction stopped with 10 mL media
that contains 10% FBS. The media used to grow the cells was RPMI-1640 with Lglutamine supplemented with 10% FBS and penicillin and streptomycin, known as
“complete media.” With the help of a hemocytometer to obtain average cell count, we were
able to dilute the cells with additional 10% FBS media until we had a solution of three
million cells per mL of media. We seeded the cells in a 96-well plate at a concentration of
30,000 cells per well. (100uL cell solution, 100uL media). The plates were cultured at 37ºC
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in a humidified 5% CO2/ 95% air environment for 24 hours. The cells were then treated
with 10 µM-0.01 µM concentration scale of vorinostat, paclitaxel, epothilone B, and
ricolinostat, and with a concentration scale of 0.1 µM - 0.0001 µM for romidepsin,
panobinostat, colchicine, and vinblastine. The plates were incubated and removed after 48
hours. To fix the cells, 100 µL of conditioned media was removed from each well, and 100
µL of a 20% trichloroacetic acid (TCA) in 1x PBS solution added. These plates were set
aside for an hour at 4ºC. The plates were washed with tap water four times and left to dry.
To the dry wells, 75 µL of SRB (0.4% w/v in 1% acetic acid) was added and allowed to
sit. After 10 minutes the plates were washed with 1% acetic acid three times then allowed
to dry. To extract the dye, 100 µL of 10 mM Tris Base was added to each well, and the
plates were gently shaken for 10 minutes on the microplate genie. Using a Spectrafluor
plate reader and Magellan software, the plates were read at 490nm with background620
nm absorbance. The inhibition of each compound on each cell line can be found because
the SRB dye binds to basic amino acids in cellular proteins of the cells [21]. The
colorimetric valuation gives an estimate of the total protein mass per well which is
proportional to cell number per well.

CLONOGENIC ASSAY:
Clonogenic assays are used to determine the effect of cytotoxic compounds on the
reproductive and proliferative properties of cells. To determine the effectiveness of the
chemotherapeutic agents used, we looked at the relative number of colonies proliferated
over a period of ten days. We tested two cells lines, MCF7-BoM and BoM-1833. We
looked at the effect of high and low concentrations of vinblastine, panobinostat,
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romidepsin, SAHA, ricolinostat, paclitaxel, epothilone B, and colchicine over three the
area six-well plates. That layout of these plates can be seen in figure 16. The cancer cells
were seeded at 3,000 cells per well and incubated for 4 hours at 37ºC to allow the cells to
adhere. The compounds were added with media at their respective concentrations to the
wells for 24 hours. At that point, the compound filled media was swapped out for fresh
(10%) FBS media with antibiotics. This was set aside for 5 days, at which time the media
was switched out again. After 10 days, the cells were fixed with methanol and stained with
crystal violet (1 mg/mL in 20% ethanol) in order to see the proliferation of the cells clearly.
The concentrations of the compounds tested were chosen based on physiological relevance
and cytotoxic potential (Table 2).
Table 2 Clonogenic assay tested concentrations
Compound

High
Concentration

Low
Concentration

Paclitaxel

1.0 µM

0.1 µM

Epothilone B

0.01 µM

0.001 µM

Colchicine

0.1 µM

0.01 µM

Vinblastine

0.1 µM

0.01 µM

SAHA

10 µM

1.0 µM

Ricolinostat

10 µM

1.0 µM

Romidepsin

0.01 µM

0.001 µM

Panobinostat

0.1 µM

0.01 µM

COMBINATION ASSAY:
We looked at histone deacetylase inhibitors in combination with other relevant
chemotherapeutic agents. The procedure we followed was very similar to that of the
viability assay. Paclitaxel and epothilone B are both microtubule stabilizer. Romidepsin,
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ricolinostat, and panobinostat were the HDAC inhibitors that we used. We combined the
stabilizers with the HDAC inhibitors as seen in figure 13. We chose to test these three
HDAC inhibitors specifically because we wanted a range of HDAC class selectivity.
Romidepsin is the most active and found to be selective for HDAC class 1. Panobinostat
is a good control inhibitor, because it is a pan HDAC inhibitor. Ricolinostat is selective for
HDAC 6. The stabilizers were selected based on their clinical effectiveness. Each
compound was tested at a concentration range based on active concentrations found on the
NCI database and taking into consideration the highest achievable concentration in patient
plasma concentrations. We set up the experiment hoping to gauge the activity of the two
compounds in combination whether they be synergistic, antagonistic, or additive.
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V
V
V
V
V
V
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V
V
V
V
V
V

V
V
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V
V
V
V

V
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Figure 13 Combination assay plate layout
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RESULTS AND DISCUSSION
VIABILITY ASSAY RESULTS:
The percent inhibition of the HDAC inhibitors, microtubule stabilizers, and
destabilizers at different concentrations in different cell lines was graphed to display any
relationship between concentration and inhibition or cell line selectivity. The graphs were
put together using the software Prism 8 (GraphPad).

None of the compounds were able to inhibit cell proliferation enough to establish
an IC50, a measure used to indicate the concentration at which a compound can inhibit cell
growth at one-half of the maximum inhibition. The IC50 is a commonly used tool which
helps to measure drug activity [22]. The concentration ranges used for the compounds may
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have been too low. In the future, more testing may help to see the effectiveness of these
compounds at higher concentrations. While IC50 values were not achieved, we did note the
concentration with the highest inhibitory effect for each compound over the three cell lines.
This can be seen in Table 3.
Table 3 Highest average Inhibitory Concentrations over three cell lines

The highlighted cells in Table 3 indicate that the highest inhibitory concentration
is the highest concentration of the compound that was tested. This is the case for almost all
of the compounds, suggesting that, if tested again at higher concentrations, the percent
Inhibition may increase with concentration. The outlier of this group of compounds was
Epothilone B, a microtubule stabilizer known for the its potency in the treatment of
paclitaxel-resistant cells [23]. Epothilone showed inhibition even at the lowest
concentration tested and had consistent inhibition over its tested concentration range. There
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was not a trend to suggest a sensitivity to increasing concentration on inhibition though.
Further testing may help to shed light onto the effect of epothilone B on these three breast
cancer cell lines.
While complete inhibition was not achieved by any of the compounds, some of the
highest inhibition percentages (74% with romidepsin) were found in the plates containing
the MCF-7 BOM cells. The MCF-7 BoM is an ER+ cell line unlike BoM and LM which
are both triple-negative breast cancers [24]. This may suggest that HDACs are more
involved in the mechanisms surrounding the ER+ breast cancer than in triple negative
breast cancer. HDAC inhibition has been connected to the inhibition of MCF-7 breast
cancer cells in previous studies. Specifically, their relationship involving the Akt serinethreonine family of kinase, which signal regulation of proliferation, protein translation, and
apoptosis [25]. The down regulation of Akt proteins is just one potential mechanism among
many that may be associated with HDAC inhibition in ER+ breast cancer.

Many

mechanistic properties involved with HDACs and HDAC inhibition are not well known,
but may play a role in cancer cell proliferation.
Another round of viability assays was performed specifically with the BoM-1833
cell line. The results of which can be seen in Figure 16.
While the mechanisms behind the HDAC inhibitors are complex and largely still
under investigation, these viability assays show a clear effect on the tumor cells. HDAC
inhibitors, whether it be epigenetically or through non-histone target, seem to inhibit
tumor cell growth in most cases.
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Figure 15 Inhibition over different drug concentrations in BOM cells.
These viability assays came out a little more strangely. Like the earlier, multi-cell
line assay, none of these were able to completely inhibit the breast cancer cells and,
therefore, IC50 values were not established. Again, these compounds should be
subsequently evaluated again at higher concentrations. These BoM assays held a general
pattern of increased inhibition with increased concentration, suggested by the prior results.
The percent inhibition in general was larger in this experiment compared to the previous
viability assay’s inhibition. This could be because of an initial decline in the health of the
BoM cells at the start of the second round of assays or a difference in lab technique
proficiency between the time of the two assays. There were also a couple of compounds
that produced a dramatic drop in inhibition at higher concentrations: panobinostat and
romidepsin. These exhibited no inhibition at their highest tested concentration. This could
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potentially be attributed to experimental error since it directly opposes the results of the
first viability assay and is such a dramatic change in effect. More testing would help to
clarify these results.
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CLONOGENIC ASSAY RESULTS:
BOM

MCF-7 BOM

Figure 16 Clonogenic Assay Plates

These clonogenic plates show that the BoM and MCF-7 BoM cell lines seem to
react similarly to each compound concentration. These results do not support cell-linedependent inhibition. None of the HDAC inhibitors are effective at their lower tested
concentrations. All of the HDAC inhibitors showed inhibition at their higher tested
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concentration, though ricolinostat appeared not as effective as the others at its higher
concentration. It is interesting that ricolinostat shows slightly different results than the other
HDAC inhibitors. This could be accounted for by a change in tested concentration, but it
is important to note that ricolinostat is the only HDAC class 2 inhibitor, being highly
selective for HDAC 6 inhibition. These HDACs are more cytoplasmic and have more nonhistone targets [16]. The slight difference could possibly be accounted for because of
mechanistic differences between the class 2 histones and the others. The microtubule
stabilizers tested (paclitaxel and epothilone B) showed apparent complete inhibition at both
high and low tested concentrations. Neither of the destabilizers tested (colchicine and
vinblastine) completely inhibited the cells at their lower concentrations.

Colchicine

seemed to inhibit the cells more fully than vinblastine at their higher tested concentration.
Overall, this assay helps to assert that there is indeed a correlation between increased
HDAC inhibitor concentration and the survival of the tumor cells.
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COMBINATION ASSAY RESULTS:

Figure 17 Combination results between Romidepsin and microtubule stabilizers

This figure shows the combination between Romidepsin, a class I selective HDAC
inhibitor and the microtubule stabilizers Paclitaxel and Epothilone B in both BOM-1833
and MCF-7 BOM metastatic breast cancer cells. Taxol by itself in this test seems to have
no inhibitory effect on the tumor cells. Epothilone B doesn’t appear to add to the percent
inhibition until it reaches higher concentrations (0.1 µM.) This is a different result than can
be seen in the viability and clonogenic assays, in which epothilone B is inhibitory at very
small concentrations. Once romidepsin and epothilone B are combined, there seems to be
a downward trend in cell inhibition. They appear to be slightly antagonistic towards each
other. As higher concentration of the HDAC inhibitor are added, the inhibition in reduced.
Taxol and romidepsin show similar antagonistic results. Both of these combination results
are supported by the National Cancer Institute (NCI) Combination Almanac database [27].
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Figure 18 Combination results between ricolinostat and microtubule stabilizers

This figure shows the combination between ricolinostat, a class II HDAC 6
selective HDAC inhibitor and the microtubule stabilizers paclitaxel and epothilone B in
both BOM and MCF-7 BOM metastatic breast cancer cells. Again, here Taxol seems to
not be inhibitory towards the cells by itself and epothilone only seems to be effective at
higher concentrations. The combination bars of these graphs are abnormal, especially
surrounding the last two concentrations groupings of both microtubule stabilizer graphs.
The results are too sporadic and opposing to make sense. There must have been some lab
error involving those combinations. Because of the lack of information surrounding higher
concentrations of epothilone B and Taxol, it is hard to say what the relationship there
appears to be between the stabilizers and HDAC 6 inhibitor. This combination should be
rerun to find more accurate and replicable results. Although the results from this assay set
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are hard to interpret the general trend seems to be more antagonistic. However, previous
research has shown that the combination treatment of paclitaxel and ricolinostat will be
synergistic in the suppression of tumor growth. In cell lines from multiple solid tumor
lineages, combination treatment with an HDAC-6 inhibitor and paclitaxel enhanced
inhibition of proliferation and increased cell death compared to either single compound
alone [26.]. Along with other effects, the inhibition of HDAC 6 results in the
hyperacetylation of α-tubulin, which increases microtubule stability. This suggests that
inhibition of HDAC 6 by selective or pan-HDAC inhibitors could increase in efficacy when
in combination with microtubule stabilizers [26.]

Figure 19 Combination results between panobinostat and microtubule stabilizers

Figure 19 shows the combination between Panobinostat, a pan selective HDAC
inhibitor and the microtubule stabilizers paclitaxel and epothilone B in both BOM and
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MCF-7 BOM metastatic breast cancer cells. Taxol and epothilone B show the same trends
of inhibition as singular compounds as in the other two combination assays. The results
suggest

an antagonistic relationship

in

both

the panobinostat/paclitaxel

and

panobinostat/epothilone B combinations. The inhibition appears to be strongest with 0.001
µM of panobinostat in all applications. The inhibition decreased as the concentration of the
HDAC inhibitor increases.
These combination assays were done in replicate with n = 2.
In future rounds of these combinations, they would be repeated with at least n = 3 in order
to ensure more accurate results.
The lack of independent inhibition from paclitaxel in all of these combinations was
initially surprising because Taxol is an established chemotherapeutic drug. But recent
studies have shown that while high doses of paclitaxel result in mitotic arrest, clinically
relevant low concentrations of paclitaxel can increase multipolar spindle formation and
subsequently increased the rate of aberrant mitosis and cell death [26].

CONCLUSIONS:
Using multiple experimental assays, the effects of HDAC inhibitors were tested on
MDA-DB-231 derivatives, BOM-1833 and LM-4175 as well as on ER+ MCF-7 BOM
metastatic breast cancer cells. Through viability assays, curves for percent inhibition were
produced which did not have enough inhibition to find IC50 values, but did have a strong
trend towards a potential for increased percent inhibition with further testing at higher
concentration ranges. The viability assay also suggested a slight selectivity of inhibition
between HDAC inhibitors and ER+ MCF-7 BOM cells over the two triple negative MDA-
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MB-231 derivative cell lines. Clonogenic assays supported the effectiveness of higher
concentrations of HDAC inhibitors on the inhibition of tumor cell growth, but presented
evidence against cell-line-dependent inhibition. When combined with microtubule
stabilizers, paclitaxel and epothilone B, the HDAC inhibitors showed an overall
antagonistic effect. These results indicate that HDACs may be valuable targets for anticancer drugs over multiple cell lines. In future research, fluorescent protein labeling could
be done to determine the molecular interactions involved in the inhibition of breast cancer
cells by the HDAC inhibitors. This might better demonstrate the potential role of nonhistone microtubule targets in tumor inhibition.
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